Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Alemtuzumab and Cyclosporine for GVHD Prevention in PBSCT
NCT00775632Phase 2Completed
- Sponsor
- University Health Network
- Start
- Oct 2008
- Primary completion
- Sep 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in graft-versus-host disease (GVHD), sponsored by University Health Network. Started Oct 2008; status: completed.
02
Drugs
alemtuzumab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00775632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00775632.